Recent interest in the control of bone metabolism has focused on a specialized subset of CD31 hi endomucin hi vessels, which are reported to couple angiogenesis with osteogenesis. However, the underlying mechanisms that link these processes together remain largely undefined. Here we show that the zinc-finger transcription factor ZEB1 is predominantly expressed in CD31 hi endomucin hi endothelium in human and mouse bone. Endothelial cellspecific deletion of ZEB1 in mice impairs CD31 hi endomucin hi vessel formation in the bone, resulting in reduced osteogenesis. Mechanistically, ZEB1 deletion reduces histone acetylation on Dll4 and Notch1 promoters, thereby epigenetically suppressing Notch signaling, a critical pathway that controls bone angiogenesis and osteogenesis. ZEB1 expression in skeletal endothelium declines in osteoporotic mice and humans. Administration of Zeb1-packaged liposomes in osteoporotic mice restores impaired Notch activity in skeletal endothelium, thereby promoting angiogenesis-dependent osteogenesis and ameliorating bone loss. Pharmacological reversal of the low ZEB1/Notch signaling may exert therapeutic benefit in osteoporotic patients by promoting angiogenesis-dependent bone formation.
A specific vessel subtype, strongly positive for CD31 and endomucin (CD31 hi EMCN hi ), has been recently reported to couple angiogenesis with osteogenesis in the bone 1-4 . CD31 hi EMCN hi vessels, residing in the bone marrow near the growth plate, represent the key component of a metabolically specialized bone microenvironment with privileged access to nutrients and oxygen, thereby promoting the growth potential of surrounding perivascular cells, including pre-osteoprogenitors, osteoprogenitors, mature osteoblasts, mature and hypertrophic chondrocytes, and hematopoietic stem cells 1-5 . It is increasingly appreciated that skeletal CD31 hi EMCN hi vessel numbers decline in ageing and ovariectomy (OVX)-induced osteoporotic mice and in osteoporotic patients 1, 4, [6] [7] [8] [9] . Osteoporosis is a systemic bone disease characterized by abnormal bone metabolism, low bone mass and density, impaired bone microstructure, and increased bone fragility and fracture prone [6] [7] [8] [9] . Reduced CD31 hi EMCN hi endothelium levels in the bone are strongly associated with osteoporosis progression. Thus, pharmacological restorage of CD31 hi EMCN hi endothelium levels in the bone may exert therapeutic benefit in osteoporotic patients by promoting angiogenesis-dependent osteogenesis. The evolutionarily conserved Dll4/Notch signaling in the bone endothelium has been reported to increase CD31 hi EMCN hi endothelium levels and thus promote bone formation by upregulating secretion levels of Noggin, a Notch-controlled angiocrine factor 2 . However, it is currently unclear how Notch activity is tightly controlled in the bone endothelium and whether declined endothelial Notch signaling is linked to osteoporosis.
Zinc-finger E-box-binding homeobox 1 (ZEB1) is most frequently characterized as a zinc-finger transcription factor that triggers the epithelial-mesenchymal transition (EMT) programs critical to development as well as a range of pathologic states, including cancer [10] [11] [12] [13] . Previous studies have demonstrated that global deletion of ZEB1 in mice elicits perinatal lethality due to severely skeletal defects 14 . However, the primary cell lineage(s) affected in these mice and the underlying molecular mechanisms remain undefined. In addition, it remains unclear whether ZEB1 is required for postnatal bone formation or whether ZEB1 loss in certain cell lineage(s) is linked to osteoporotic disease in human and mice. Here we show that ZEB1 is predominantly expressed in CD31 hi EMCN hi endothelium in human and mouse bone, and ZEB1 levels decline in ageing and OVX-induced osteoporotic mice, as well as in osteoporotic patients. Endothelial cell (EC)specific deletion of ZEB1 in mice reduces CD31 hi EMCN hi vascularization and osteogenesis by epigenetically repressing Dll4/ Notch signaling. Administration of recombinant Dll4 protein efficiently restores CD31 hi EMCN hi vessel growth and bone formation in ZEB1-deleted mice. Importantly, we observe low ZEB1-Dll4/Notch signaling in OVX-induced osteoporotic mice and in vivo ZEB1 gene delivery restores impaired Notch signaling, thereby boosting CD31 hi EMCN hi vessel formation, promoting osteogenesis, and ameliorating bone loss in OVX-induced osteoporotic mice. In summary, our results lay the foundation for new therapeutic strategies in osteoporosis treatment by promoting angiogenesis-dependent bone formation.
Results
ZEB1 is predominantly expressed in CD31 hi EMCN hi bone ECs. We scanned tissues that were collected from juvenile 3-week-old mice for ZEB1 protein expression. Interestingly, we found that ZEB1, as detected by immunofluorescence, was expressed in the endothelium of skeletal elements such as the tibia, sternum, and vertebra at significantly higher positivity and expression levels than in the endothelium of non-skeletal organs such as the spleen, lung, kidney, liver, and heart ( Fig. 1a, b) . Further, we observed that ZEB1 protein was predominantly expressed in metaphyseal CD31 hi EMCN hi (termed as type H) endothelium of tibia, while it was essentially undetectable in the CD31 low EMCN low (termed as type L) endothelium found within the bone marrow ( Fig. 1c, d) . These observations suggest a markedly distinct ZEB1 expression pattern between type H and L vessels in mouse long bone (e.g., tibia), a finding that could be extended to other skeletal elements such as the sternum, calvarium, and vertebra ( Fig. 1c, d) . Importantly, the distinct ZEB1 expression pattern observed in mouse bone was also presented in human tibia (Fig. 1c, d ). Furthermore, we performed a quantitative reverse transcription PCR (RT-qPCR) assay on fluorescence-activated cell (FACS)sorted type H vs. type L tibial ECs of 3-week-old mice. The results demonstrated that Zeb1 transcript levels in type H tibial ECs were also significantly higher than in type L ECs (Fig. 1e ). Intriguingly, transcript levels of Zeb2, another member of ZEB family, in type H bone ECs were remarkably lower than in type L ECs, an expression pattern that is highly distinct from ZEB1 in bone ECs (Fig. 1e ). It has been previously reported that type H vessel numbers and bone mass decline in tandem with ageing in human and murine skeletal system 1,6 ( Fig. 1f-h) . Notably, ZEB1 protein in type H tibial ECs was remarkably more abundant in juvenile (3-week-old) mice relative to (10-week-old) adults and was largely absent in aged (50-week-old) animals ( Fig. 1h , i), suggesting that ZEB1 protein is dynamically controlled during ageing. On the basis of the specific expression pattern of ZEB1 in the skeletal system, we considered the possibility that ZEB1 expressed by type H bone ECs functions as a key signaling regulator of angiogenesis and bone formation.
Endothelial ZEB1 deletion reduces type H vessel formation. To investigate ZEB1 function in the bone endothelium, conditional Zeb1 floxed/floxed (Zeb1 fl/fl ) mice were generated in our laboratory ( Supplementary Fig. 1a ; ref. 15 ) and crossed with Tie2-Cre 16, 17 transgenic line to generate Tie2-Cre − ;Zeb1 fl/fl control and Tie2-Cre + ;Zeb1 fl/fl EC-specific ZEB1 knockout mice (designated Zeb1 WT and Zeb1 ΔEC mice, respectively). In addition, Zeb1 fl/fl mice were also mated with Cdh5(PAC)-CreERT2 18 transgenic line and the resulting Cdh5(PAC)-CreERT2 -;Zeb1 fl/fl and Cdh5(PAC)-CreERT2 + ;Zeb1 fl/fl mice were treated with tamoxifen to generate control and EC-specific ZEB1 knockout mice (designated Zeb1 WT and Zeb1 iΔEC mice, respectively). RT-qPCR analysis of FACSsorted tibial ECs revealed significantly reduced Zeb1 transcript levels in 3-week-old Zeb1 ΔEC compared with control littermates ( Supplementary Fig. 1b , c). Also, Zeb1 transcript levels were remarkably decreased in tibial ECs of 3-week-old Zeb1 iΔEC mice that were intraperitoneally (i.p.) injected with 0.1 mg tamoxifen every day at postnatal day 8 (P8) for 7 consecutive days, as compared with Zeb1 WT control mice receiving identical tamoxifen treatment ( Supplementary Fig. 1c ). Furthermore, immunofluorescence analysis of tibial sections revealed that ZEB1 protein was efficiently depleted in type H bone ECs but not perivascular cells of 3-week-old Zeb1 ΔEC mice ( Supplementary Fig. 1d , e) and Zeb1 iΔEC mice ( Supplementary Fig. 1f , g). Constitutive and tamoxifen inducible inactivation of endothelial ZEB1 in 3-weekold mice markedly decreased the density of type H vessels, but not type L vessels, in skeletal elements such as tibia, sternum, vertebra, and calvarium, as assessed by immunofluorescence ( Fig. 2a-c and Supplementary Fig. 2a , b) and FACS ( Fig. 2d, e ) analyses. Similarly, 10-week-old adult Zeb1 ΔEC mice and Zeb1 iΔEC mice that were i.p. injected with 1.0 mg tamoxifen every other day at 7 weeks of ages for 2 consecutive weeks both exhibited substantially reduced type H but not type L vessel density compared with their corresponding littermate controls ( Supplementary  Fig. 2c-f ). By contrast, Zeb1 ΔEC mice exhibited comparable CD31 + vessel densities in non-skeletal tissues such as the heart, lung, liver, kidney, and spleen relative to littermate controls ( Supplementary Fig. 2g , h). Vascular endothelial growth factor A (VEGFA), a potent proangiogenic growth factor secreted by endothelial column/arches, perivascular cells, and mature/ hypertrophic chondrocytes 19 , was robustly decreased in the tibia of 3-week-old Zeb1 ΔEC mice, as assessed by immunofluorescence analysis (Fig. 2f, g) . RT-qPCR analysis of FACS-sorted tibial ECs also revealed a strong reduction in Vegfa transcript levels in 3week-old Zeb1 ΔEC mice compared with littermate controls (Fig. 2h ). These findings are consistent with previous reports demonstrating that ZEB1 is positively associated with VEGFA expression in cancer cells 20 Endothelial ZEB1 deletion impairs bone formation. Severely defective angiogenesis in the skeletal organs of Zeb1 ΔEC mice at 3, 10, and 50 weeks of ages was accompanied by significantly reduced body weight and shortened femoral length ( Fig. 3a and Supplementary Fig. 3a ). Micro-computed tomography (micro-CT) and histo-morphometric analyses revealed significant loss of trabecular bone density (trabecular bone volume per tissue volume (Tb. BV/TV)), trabecular number (Tb. Nb.), trabecular thickness (Tb. Th.), and cortical thickness (Ct. Th.) in the tibia of 3-, 10-, and 50-week-old Zeb1 ΔEC mice (Fig. 3b , c and Supplementary Fig. 3b-d ). By contrast, no structural alterations were detected in 3-week-old Zeb1 ΔEC non-skeletal organs such as the heart, liver, spleen, lung, and kidney ( Supplementary Fig. 3e ). Notably, 3-week-old Zeb1 iΔEC mice also exhibited markedly reduced body weight ( Supplementary Fig. 3f , left two columns) in tandem with severely impaired bone formation ( Supplementary  Fig. 3g , h). As body weight is believed to have a profound impact on bone mass, we further assessed whether impaired bone formation observed in endothelial ZEB1-deleted mice was due to reduced body weight of the mice. To this end, we induced endothelial ZEB1 deletion in mice at 7 weeks of ages, a stage that skeletal growth has been completed. As shown, body weight of 10-week-old adult Zeb1 WT and Zeb1 iΔEC mice was largely comparable ( Supplementary Fig. 3f , right two columns), whereas bone mass of Zeb1 iΔEC mice was significantly lower than Zeb1 WT mice, as assessed by micro-CT analysis ( Supplementary Fig. 3i , j). Thus, these findings demonstrate that endothelial ZEB1 deletion at young or adult ages both elicits impairment of bone formation independently of body weight reduction in the mice. Calcein double labeling further confirmed strongly reduced bone formation rates in the tibia of 3-week-old Zeb1 ΔEC mice ( Fig. 2d, e ). Importantly, 3-week-old Zeb1 ΔEC and Zeb1 iΔEC mice showed significantly reduced numbers of Runx2 + pre-osteoprogenitors 21 , Osterix + osteoprogenitors 22 , as well as ALP + mature osteoblasts 23 in tandem with impaired mineralized bone mass (Alizarin staining), but without appreciable changes in the TRAP + preosteoclasts numbers 24 (Fig. 3f-l and Supplementary  Fig. 4a-d ). Consistent with the changes observed in 3-week-old juvenile bone, substantially reduced numbers of Runx2 + preosteoprogenitors and Osterix + osteoprogenitors were also detected in 10-week-old adult Zeb1 ΔEC tibia ( Supplementary  Fig. 4e , f). Similarly, no considerable change in the TRAP + osteoclasts numbers was observed in the tibia of 10-week-old Zeb1 ΔEC mice compared with Zeb1 ΔEC mice ( Supplementary  Fig. 4g , h).
ZEB1 depletion represses Dll4/Notch signaling in bone ECs.
To investigate the potential mechanisms by which endothelial ZEB1 regulates bone angiogenesis and osteogenesis, bone ECs of Zeb1 WT and Zeb1 ΔEC mice were freshly isolated and subjected to RT-qPCR screening analysis. As shown, transcript levels of Dll4, Notch1, Notch2, Notch3, Notch4, Hes1, Hes5, Hey1, Heyl, and Efnb2 were markedly reduced in Zeb1 ΔEC mice, suggesting that the Notch signaling was downregulated in the Zeb1 ΔEC bone ECs ( Fig. 4a ). Intriguingly, Zeb2 transcript levels were also remarkably decreased in Zeb1 ΔEC bone ECs ( Fig. 4a ), suggesting that ZEB1 excision in bone ECs does not induce a compensatory increase in Zeb2 expression but markedly reduces its expression. Further, immunofluorescence analysis revealed that expression levels of Dll4 and Notch1 in EMCN + bone ECs were markedly decreased in the tibia of Zeb1 ΔEC and Zeb1 iΔEC mice relative to their corresponding littermate controls ( Fig. 4b, e ). To assess whether ZEB1 controls Notch activity in an EC-autonomous manner, we performed a RT-qPCR assay on the in vitro cultured bone ECs that were isolated from Zeb1 fl/fl tibia and infected with adeno-βGal or adeno-Cre (to generate control and ZEB1-deleted cells, respectively). The results showed a significant reduction in transcript levels of Zeb1, Zeb2, and key components of Dll4/ Notch pathway in ZEB1-deleted bone ECs relative to control cells ( Fig. 4f , g). Protein levels of Dll4, Notch1, and the intracellular domain of Notch1, NICD1 (which is the active form of Notch1), were strongly decreased in ZEB1-deleted bone ECs compared with control cells, as assessed by immunoblot and immunofluorescence analyses ( Fig. 4h , i). Similar to a well-established zinc-finger transcription factor Snail1 [25] [26] [27] , ZEB1 acts as a transcriptional repressor/activator by directly binding to E-box elements (consensus sequence, CANNTG), which are located within the promoter regions of target genes 28, 29 . In this regard, initial searches identified multiple conserved E-box elements within the proximal regions of the murine Dll4 and Notch1 promoters ( Fig. 5a ). Indeed, ZEB1deleted bone ECs markedly decreased luciferase activity of wildtype (WT) Dll4 and Notch1 reporter constructs, without affecting luciferase activity of mutant (MUT) Dll4 and Notch1 reporter constructs harboring successive point mutations in all E-boxes ( Fig. 5b ). In control bone ECs, luciferase activity of MUT Dll4 and Notch1 reporter constructs was significantly lower than corresponding WT reporter constructs, confirming that ZEB1 functions as a transcription activator of Dll4 and Notch1 genes ( Fig. 5b ). Conversely, exogenous ZEB1-expressing bone ECs remarkably increased luciferase activity of WT Dll4 and Notch1 reporter constructs, wereas it failed to affect luciferase activity of MUT Dll4 and Notch1 reporter constructs ( Fig. 5c ). After chromatin immunoprecipitation (ChIP) of endogenous ZEB1 in bone ECs followed by PCR of the proximal and distal regions of the murine Dll4 and Notch1 promoters, ZEB1-ChIPs were found ECs of the tibia, sternum, vertebra, spleen, lung, and kidney dissected from juvenile 3-week-old mice (n = 5). Nuclei, 4',6-diamidino-2-phenylindole (DAPI). Magnified areas of dashed boxed sections are shown in right panels. gp growth plate. Scale bar, 30 μm. b Quantification of positivity of ZEB1 + ECs as shown in a (n = 5 independent experiments). c Comparisons of ZEB1 staining levels in CD31 hi EMCN hi (type H) vs. CD31 lo EMCN lo (type L) ECs of 3-weekold tibia, sternum, vertebra, and calvarium (n = 5), and human tibia (n = 3). Magnified areas of dashed boxed sections in top row are shown in right panels. bm bone marrow, EMCN endomucin. Scale bar: 30 μm, 200 μm (top row, lower magnification images). d Quantification of ZEB1 staining levels in two types of bone ECs as shown in c (n = 5 or 3 independent experiments). e RT-qPCR analysis of Zeb1 and Zeb2 transcripts in FACS-sorted type H and type L bone ECs of 3-week-old mice (n = 3 independent experiments). f Representative micro-CT images of trabecular bone of 3-, 10-, and 50-week-old tibia (n = 5). Scale bar, 0.2 mm. g Quantification of trabecular bone fraction (Tb. BV/TV; trabecular bone, bone volume/tissue volume) and trabecular number (Tb. Nb.) in tibia as shown in f (n = 5 independent experiments). h Representative confocal images of ZEB1, CD31, and EMCN immunostained sections of 3-, 10-or 50-week-old tibia (n = 5, each). Scale bar, 30 μm. i Quantification of ZEB1 staining levels in tibial type H ECs as shown in h (n = 5 independent experiments). All data are represented as mean ± SD. **P < 0.01; NS not significant. Differences are tested using one-way ANOVA with Tukey's post hoc test (b, g, i) and unpaired two-tailed Student's t-test (d, e). The source data are provided as a Source Data file.
to be enriched in the proximal, but not distal, regions of both promoters, suggesting that ZEB1 activated Dll4 and Notch1 transcription by specifically binding to promoter proximal regions ( Fig. 5d, e ). The ability of zinc-finger transcription factors (e.g., Snail) to transactivate target genes has been linked to the recruitment of histone-modifying cofactors to the promoters of target genes, which can specifically enhance histone acetylation but not methylation on the promoters 25, 30 . ChIP-qPCR analysis showed that ZEB1-deleted bone ECs significantly reduced histone acetylation, including histone H3 lysine 4 acetylation (H3K4Ac), H3K14Ac, and H3K18Ac, on the promoters of Dll4 and Notch1, without affecting recruitment of histone H3 lysine 27 trimethylation (H3K27me3), a reported repressive histone marker 25, 31 ( Fig. 5f ). To uncover the cofactors that are responsible for histone acetylation on the promoters of Dll4 and Notch1, we performed co-IPexperiments in bone ECs. The results demonstrated that ZEB1 was associated with histone acetyltransferases (HATs), CREB-binding protein (CBP)/p300 in bone ECs (Fig. 5g ). Sequential ChIP analyses revealed that ZEB1 and CBP cooccupied Dll4 and Notch1 promoters in bone ECs (Fig. 5h) . A promoter luciferase reporter assay was then performed in 293T cells that were transiently transfected with HA-ZEB1, HA-p300, or HA-CBP alone, or ZEB1 in combination with p300 or CBP (Fig. 5i ). The results showed that overexpression of ZEB1, p300, or CBP alone increased Dll4 (Notch1) promoter activity by 88% (75%), 20% (16%), or 23% (15%), respectively, whereas Fig. 5a ). Importantly, the impaired expression of NICD1 in ZEB1-deleted bone ECs was also fully recovered following r.Dll4 treatment, as assessed by immunofluorescence and immunoblot analyses ( Fig. 6a, b ), suggesting that ZEB1-deleted bone ECs with impaired Notch activity were responsive to Dll4 stimulation. Our findings are consistent with previous reports demonstrating that treatment of muscle satellite cells and ECs with r.Dll4 protein robustly stimulates Notch activity 32, 33 . Daily injection of Zeb1 WT mice with 1 μg/g r.Dll4 protein for 2 consecutive weeks (starting from P4) before analysis at P21 markedly increased protein expressions of Dll4 and Notch1 in the tibia ( Supplementary Fig. 5b ), but had no obvious impact on body weight ( Supplementary Fig. 5c ), bone angiogenesis ( Fig. 6c, d ), or osteogenesis ( Fig. 6e-h) . In sharp contrast, administration of Zeb1 ΔEC mice with r.Dll4 protein remarkably restored body weight ( Supplementary Fig. 5c ), enhanced type H vessel formation and VEGFA expression in the tibia (Fig. 6c, d) , improved bone formation (Fig. 6e, f) , and normalized the numbers of Runx2 + pre-osteoprogenitors, Osterix + osteoprogenitors, and ALP + mature osteoblasts (Fig. 6g, h) . Recently, angiocrine factors secreted by vascular niche have been reported to play critical roles in promoting organ development, tumor growth, and tissue regeneration 34, 35 . We therefore sought to identify potential pro-osteogenic factors that are actively involved in regulation of endothelial Notch-dependent osteogenesis. As shown, Fig. 5d ). Our data demonstrate that Dll4/Notch1 signaling pathway is actively involved in the regulation of endothelial ZEB1 on bone angiogenesis and osteogenesis.
Zeb1 gene delivery alleviates OVX-induced bone loss. Evidence to date indicates that type H vessel numbers are significantly lower in the bone of osteoporotic humans and mice 4,6-8 . Notably, ZEB1 expression was significantly reduced in bone ECs of osteoporotic patients relative to normal controls, a finding accompanied by substantially decreased densities of total vessels and type H vessels (Fig. 7a, b ). Based on these findings, we decided to determine whether pharmacological administration of exogenously expressed ZEB1 could ameliorate osteoporosis using a DNA-loaded cationic liposome vehicle [36] [37] [38] and an OVX mouse model 4, 8 .
To directly assess the efficiency and specificity of cationic liposome-delivered Zeb1 gene in vivo, we generated a pcDNA3.1 +C-eGFP-ZEB1 vector (designed ZEB1-GFP) that can express recombinant enhanced greenfluorescent protein (eGFP)-fused ZEB1 protein in the target cells. Next, pcDNA3.1+C-eGFP (designed Vector-GFP) or ZEB1-GFP was mixed with cationic protamine at different N:P ratios (the molar ratio of nitrogen in protamine to phosphate in DNA vector) to form the nano-sized DNA/protamine complex (designed Protamine-Vector-GFP and Protamine-ZEB1-GFP). DNA packing efficiency was examined by agarose gel electrophoresis. The results showed that protamine can completely condense Vector-GFP and ZEB1-GFP at the N:P ratio of 3:1 and 4:1, respectively ( Supplementary Fig. 6a ). Protamine-Vector-GFP or Protamine-ZEB1-GFP was subsequently mixed with cationic liposomes at 60 nmol lipid/μg DNA to generate Lipo.-Vector-GFP and Lipo.-ZEB1-GFP, respectively. Agarose gel electrophoresis analysis revealed that Vector-GFP and ZEB1-GFP were completely encapsulated in the cationic liposomes under these conditions ( Supplementary  Fig. 6b ). The final Lipo.-Vector-GFP had a particle size of 151.2 ± 5.7 nm (mean ± SD), a zeta potential of +24.9 ± 1.6 mv, and a polymer dispersity index of 0.286 ± 0.017, respectively, whereas the final Lipo.-ZEB1-GFP had 147.5 ± 4.9 nm, 23.8 ± 2.1 mv, and 0.270 ± 0.017, respectively ( Supplementary Fig. 6c Supplementary Fig. 6e ). We next sought to analyze biodistribution of the DNA-packaged liposomes. For this purpose, ZEB1-GFP was packaged into 1,1'dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide (DiR)-labeled liposomes and the DNA-packaged liposomes (designed DiR-Lipo.-ZEB1-GFP) were i.v. injected into adult mice; the kidneys, spleen, lungs, brain, heart, liver, and hind limbs were dissected 24 h post injection and subjected to ex vivo biophotonic imaging analysis. As shown, the DiR signal was readily detected in the hind limbs, liver, spleen, lung, and kidneys, whereas the signal was hardly undetectable in the brain and heart ( Supplementary Fig. 6f, g) , validating efficient distribution of DiR-Lipo.-ZEB1-GFP to the skeletal and non-skeletal organs.
To generate OVX and sham-operation (Sham) mouse models, the surgery was performed on 8-week-old female mice and the mice at day 3 post surgery were i.v. injected with 4 μg Lipo.-Vector-GFP or Lipo.-ZEB1-GFP twice every week for consecutive 6 weeks. As predicted, uterine weight of OVX mice was reduced by 75% compared with Sham mice, whereas uterine weight of OVX mice treated with Lipo.-Vector-GFP or Lipo.-ZEB1-GFP was largely comparable ( Supplementary Fig. 7a, b ). To examine expressions of liposome-delivered Vector-GFP and ZEB1-GFP in target cells, the tibia and non-skeletal tissues were dissected for immunofluorescence analysis. The results revealed that liposomedelivered Vector-GFP and ZEB1-GFP were predominantly expressed in the metaphysis of the tibia (Fig. 7c ) with remarkably lower expressions in the diaphysis of the tibia and non-skeletal tissues such as the lung, liver, and spleen ( Supplementary Fig. 7c ). Notably, a large proportion of GFP + cells was identified as EMCN + bone ECs, indicating that bone ECs in the metaphysis of the tibia are the major target cells of Lipo.-Vector-GFP and Lipo.-ZEB1-GFP (Fig. 7c ). However, a small proportion of GFP + cells can be identified as EMCN − perivascular cells that may also respond to the liposome treatment ( Fig. 7c ). Furthermore, Vector-GFP recombinant protein was localized in cytoplasmic fraction of metaphyseal cells (in green; Fig. 7c , left and middle panels), whereas ZEB1-GFP recombinant protein was localized in the nucleus of metaphyseal cells (in yellow; Fig. 7c, right panels) . In OVX mice treated with Lipo.-ZEB1-GFP, the positivity of endogenous ZEB1 + bone ECs (i.e., the ratio of red/white: white) and exogenous ZEB1 + bone ECs (i.e., the ratio of yellow/white: Fig. 4 Endothelial ZEB1 inactivation downregulates Notch activity. a RT-qPCR analysis of Zeb1, Zeb2, Dll4, Notch1, Notch2, Notch3, Notch4, Hes1, Hes5, Hey1, Heyl, and Efnb2 in FACS-sorted bone ECs of 3-week-old Zeb1 WT and Zeb1 ΔEC mice (n = 3 independent experiments). b, c Representative confocal images of Dll4 (left panels) and Notch1 (right panels) immunostaining in the tibia of 3-week-old Zeb1 ΔEC mice (b; n = 5) and Zeb1 iΔEC mice (c; n = 5), and their corresponding littermate controls (n = 5, each). Scale bar, 60 μm. d Quantification of Dll4 (left panels) and Notch1 (right panels) staining levels in EMCN + bone ECs of 3-week-old Zeb1 WT and Zeb1 ΔEC mice as described in b (n = 5 independent experiments). e Quantification of Dll4 (left panels) and Notch1 (right panels) staining levels in EMCN + bone ECs of 3-week-old Zeb1 WT and Zeb1 iΔEC mice as described in c (n = 5 independent experiments). white) was 13.4% and 28.3%, respectively, suggesting that exogenous recombinant ZEB1 protein was efficiently delivered to and expressed in EMCN + bone ECs (Fig. 7c, d) . Endogenously expressed ZEB1 protein levels in bone ECs of OVX mice were decreased by 60% compared with Sham mice, and the levels of ZEB1 protein (including endogenously and exogenously expressed ZEB1) in bone ECs of OVX + Lipo.-ZEB1-GFP mice were restored to 90% those of Sham + Vector-GFP mice (Fig. 7c,  d) . Importantly, the impaired type H vessel formation in tibial metaphysis of OVX mice was efficiently recovered following Lipo.-ZEB1-GFP treatment (Fig. 7e, f) . Accordingly, the diminished expressions of Dll4 and Notch1 proteins in EMCN + bone ECs of OVX mice were also considerably restored following Lipo.-ZEB1-GFP treatment (Fig. 7g, h) . 
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As predicted, micro-CT analysis demonstrated that tibia of OVX mice exhibited increased cross-sectional endosteal perimeters (might due to bone loss at the endosteum) in tandem with remarkably decreased Ct. Th., trabecular bone density, Tb. Nb., and Tb. Th. compared with Sham mice (Fig. 8a, b) . Notably, administration of OVX mice with Lipo.-ZEB1-GFP efficiently restored the impaired bone formation in the mice (Fig. 8a, b ). Immunofluorescence analysis further revealed that tibia of OVX mice had significantly lower numbers of Runx2 + preosteoprogenitors and Osterix + osteoprogenitors than Sham mice (Fig. 8c, d) , which is consistent with previous reports demonstrating that numbers of Runx2 + and Osterix + cells are strongly reduced in OVX bone [39] [40] [41] . As predicted, administration of OVX mice with Lipo.-ZEB1-GFP efficiently normalized the numbers of Runx2 + pre-osteoprogenitors and Osterix + osteoprogenitors (Fig. 8c, d) . To evaluate whether repeated treatments with Lipo.-ZEB1-GFP or Lipo.-Vector-GFP could induce any histological alterations in major organs, we harvested major organs such as the lung, spleen, heart, liver, and kidney of liposome-treated mice for histo-morphometric analysis. Importantly, the results showed that administration of Sham or OVX mice with Lipo.-ZEB1-GFP or Lipo.-Vector-GFP for consecutive 6 weeks failed to induce any detectable histological alterations in the major organs, supporting the absence of Lipo.-ZEB1-GFP-or Lipo.-Vector-GFP-induced side toxicity ( Supplementary Fig. 7d ).
Discussion
In the present study, we unexpectedly found that EMT-associated transcription factor (EMT-TF) ZEB1 is predominantly expressed in type H vascular endothelium in human and murine bone. Type H vessels primarily reside in the bone marrow near the growth plate but are essentially undetectable in non-skeletal organs 1-4 .
Recent studies have demonstrated that type H endothelium impacts bone architecture, bone formation, and the recruitment of perivascular osteoprogenitor 1-4 . EC-specific deletion of ZEB1 strongly reduces type H vessel growth and bone formation but does not affect vasculature growth or cause histological alterations in the non-skeletal organs. The considerably variable consequences of ZEB1 depletion in ECs are due to the highly differential expression of ZEB1 in skeletal type H endothelium vs. non-skeletal endothelium. The EMT activator ZEB1 is largely a transcriptional repressor. ZEB1 silencing in mesenchymal cancer cells restores transcription of CDH1 (encoding E-cadherin), a hallmark of EMT programs 10, 11 . However, ZEB1 deletion in bone ECs does not affect CDH1 transcription but indeed decreases histone acetylation on Dll4 and Notch1 promoters, thereby directly suppressing their transcriptional activity and downregulating endothelial Notch signaling. The evolutionarily conserved Notch signaling pathway plays critical roles in controlling multiple aspects of vascular development and EC function, ranging from proliferation, motility, and lumen formation to vessel stability and cell fate determination 42, 43 . Notch signaling has been identified as a critical positive regulator of vascular growth in bone, which is highly distinct from the Notch-mediated suppression of vessel sprouting in non-skeletal organs and in malignant tumors [44] [45] [46] . A recent report has demonstrated that ZEB1 indirectly upregulates Notch signaling by reducing miR-200 expression in multiple tumor cell lines 47 . Here we demonstrate that ZEB1 interacts with HATs CBP/p300 and they co-occupy the promoters of Dll4 and Notch1 to enhance histone acetylation on the promoters, thus directly inducing transcriptional activation of Dll4 and Notch1 in bone ECs. Our results further demonstrate that ZEB1/Notch signaling axis plays an essential role in controlling type H bone vessel formation. Notch signaling has been reported to promote bone-specific angiogenesis and osteogenesis in both autocrine and paracrine manners 2 . Here we found that ZEB1/Notch signaling pathway controls recruitment/differentiation of perivascular osteoprogenitors and consequently promotes osteogenesis in the bone by regulating expression of multiple angiocrine factors such as TGFβ1, TGFβ2, BMP2, BMP4, FGF1, and Noggin. All these angiocrine factors are believed to actively participate in osteogenesis. Future work will address the mechanisms by which these angiocrine factors regulate differentiation and recruitment of osteoprogenitors in Zeb1 ΔEC bone microenvironment.
In the present study, we observe that the impaired bone angiogenesis and osteogenesis in OVX mice are efficiently restored following systematic treatment with ZEB1-GFPpackaged cationic liposomes. Although an efficient distribution of DNA-packaged cationic liposomes to the bone and various non-skeletal organs is observed, the liposome-delivered plasmid DNAs are predominantly expressed in the metaphysis of the tibia (mostly in type H bone ECs) with remarkably lower expressions in the diaphysis of tibia and non-skeletal elements. One possible explanation for the considerable difference between the organ distribution of DNA-packaged liposomes and expression of liposome-delivered plasmid DNA in target cells is that metaphyseal cells with highly metabolic activity 1 are more prone to uptake and express plasmids DNA than cells in the diaphysis of tibia and non-skeletal tissues. Consistent with this observation, no detectable histological alterations in non-skeletal organs such as the heart, liver, spleen, lung, or kidneys are observed after a 6week course of systematic treatment of OVX mice with DNApackaged cationic liposomes, supporting the absence of liposome-ZEB1-GFP-or liposome-Vector-GFP-induced toxicity or side effects. ZEB1 is inappropriately upregulated in a variety of malignant tumor types and functions as a stimulating factor of tumor invasion and metastasis [10] [11] [12] [13] . Whether ectopic expression of ZEB1 in normal cells (e.g., metaphyseal cells) could induce transformation of the cells is still elusive. Future work will determine whether the extended period of treatment with Zeb1packaged liposomes is still safe to the animals.
In conclusion, our results more broadly suggest that Zeb1packaged cationic liposomes targeting bone vasculature may have a synergistic or complementary effect when used in combination with an osteoblast-targeted anabolic such as a parathormone analog or an anti-sclerostin antibody. The findings presented here lay the foundation for new therapeutic strategies in the treatment of osteoporotic disease states by promoting angiogenesisdependent osteogenesis.
Methods
Mice. Mice were housed under standard specific-pathogen-free conditions and all animal experiments were performed in accordance with protocols that were approved and authorized by the Animal Welfare and Ethics Committee of China Pharmaceutical University. Mice carrying Zeb1 (exon 3) floxed alleles (Zeb1 fl/fl ) were generated in our laboratory and have been described previously 15 . Tie2-Cre transgenic mice were purchased from Jackson Laboratory (#008863). Cdh5(PAC)-CreERT2 transgenic mice were kindly provided by Ralf H. Adams (Max Planck Fig. 6 Administration of Zeb1 ΔEC mice with r.Dll4 protein efficiently restores the impaired bone angiogenesis and osteogenesis. a, b Control and ZEB1deleted bone ECs seeded on vehicle-or r.Dll4-precoated chamber wells (or culture dishes) were subjected to NICD1 immunostaining (a) and immunoblotting (b) analyses, respectively. Representative confocal or immunoblot images as shown are from three independent experiments. Scale bar, 20 μm. c Representative confocal images of CD31/EMCN and VEGFA immunostaining in the tibia of Zeb1 WT and Zeb1 ΔEC mice that were i.p. injected with 1 μg/g r.Dll4 protein at P4 for 2 consecutive weeks before analysis at P21 (n = 5, each). Scale bar, 100 μm. d Quantification of type H vessel density (top panel) and VEGFA staining levels (bottom) in the tibia as shown in c (n = 5 independent experiments). e Micro-CT analysis of the tibia showing improved bone formation in trabecular bone (top panels) and cortical bone (bottom panels) of Zeb1 ΔEC mice treated with r.Dll4 protein as described in c (n = 5, each). Scale bar, 0.2 mm. f Quantification of bone architectures in the tibia as shown in e (n = 5 independent experiments). g Runx2, Osterix, and ALP immunostaining of the tibia as described in c (n = 5, each). Scale bar, 100 μm. h Quantification of Runx2 + , Osterix + , and ALP + cells in the tibia as shown in g (n = 5 independent experiments). All data are represented as mean ± SD. **P < 0.01. Differences are tested using one-way ANOVA with Tukey's post hoc test (d, f, h) . The source data are provided as a Source Data file. Unprocessed original scans of blots are shown in Source Data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14076-3 ARTICLE Institute for Molecular Biomedicine, Münster, Germany 18 ). For generation of intrinsic and inducible EC-specific ZEB1-deleted mice, Zeb1 fl/fl mice were bred with Tie2-Cre and Cdh5(PAC)-CreERT2 transgenic mice, respectively. To induce Cdh5(PAC)-CreERT2 activity and gene inactivation in pups, mice at P8 were i.p. injected with 0.1 mg tamoxifen (10 μl, 10 mg/ml, dissolved in 1:10 ethanol/corn oil; Sigma-Aldrich, #T5648) every day for 7 consecutive days. To induce gene inactivation in adults, 7-week-old mice were i.p. injected with 1.0 mg tamoxifen (100 μl, 10 mg/ml) every other day for 2 consecutive weeks. For r.Dll4 administration experiments, Zeb1 WT and Zeb1 ΔEC mice were i.p. injected with 1 μg/g r.Dll4 protein (R&D Systems, #1389-D4-050) at P4 for 2 consecutive weeks before analysis at P21. To generate OVX and Sham mouse models, the surgery was performed on 8week-old female mice, and the mice at day 3 post surgery were i.v. injected with 4 μg Lipo.-Vector-GFP or Lipo.-ZEB1-GFP twice every week for consecutive 6 weeks. Mice were then killed and uterine, long bone, and non-skeletal organs were dissected for further use. All mice were kept in C57BL/6J background and gender-matched littermate controls were used in all experiments. The investigators were not blinded to allocation during experiments and outcome assessment. No method of randomization was used as mice were segregated into groups based on genotype alone. No statistical method was used to predetermine sample size.
Genotyping. Tail biopsy (~2 mm) samples were digested at 95°C for 30 min in 50 μl of buffer 1 (10 N NaOH and 0.5 M EDTA pH 12.0). An equal amount of buffer 2 (40 mM Tris-HCl pH 5.0) was added to neutralize buffer 1. The mixtures were immediately vortexed and centrifuged at 12,000 × g for 5 min. The supernatants (containing genomic DNAs) were collected and stored in −20°C for further use. One microliter of extracted genomic DNA was added to 20 μl of PCR reaction mixture containing 10 μl 2× GoTaq Green Master Mix (Promega, #M7123), 0.5 μl forward/reverse primers, and 8.5 μl RNase/DNase free H 2 O. Primer sequences for amplifying the indicated mouse transgenes are as follows. 
